Eugit Therapeutics
Enabling Tissue Targeting of Therapies
What they do
Non-specific systemic drugs cause off-target toxicity and clinical trial failures for patients with tissue-specific inflammatory diseases.
TAGHOME uses T cell receptor-based tissue targeting to deliver therapies precisely to diseased tissues, improving safety and efficacy.
Patients with tissue-specific inflammatory diseases (initially Inflammatory Bowel Disease) treated by healthcare providers.
Founders
Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.
Company timeline
- Founded2022
- YC batchSummer 2022
- StatusActive
- Team size2 people
- LocationSan Francisco, CA, USA; South San Francisco, CA, USA
Similar startups
